DB05160InvestigationalSmall molecule
Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
- Mechanism
- Curator reviewed
PRX302 is a targeted pro-drug that turns into a potent anti-cancer agent once activated by the enzyme, prostate specific antigen (PSA), produced in high levels by prostate cancer and hyperplastic prostate cells. Once activated, PRX302 destroys the cells by punching holes in the cell membrane.
- Primary indication
- Investigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.Curator reviewed
- Code names
- PRX-302
Resolves to
Compound
Targets
What you can answer from here — as of July 03, 2026
Which drugs share a target with Topsalysin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account